Straits Times Index
3,116.32 +14.39 (+0.46%) S&P 500
4,538.43 -38.67 (-0.84%) Dow
34,580.08 -59.72 (-0.17%) Nasdaq
15,085.47 -295.83 (-1.92%) BTC-USD
48,559.04 -920.55 (-1.86%) CMC Crypto 200
1,238.66 -203.10 (-14.09%)
Seres Therapeutics, Inc. (MCRB)
Pre-market:
- Motley Fool
Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday
Shares of Seres Therapeutics (NASDAQ: MCRB) climbed more than 21% on Tuesday. The biotech stock, which closed at $8.82 on Monday, opened at $8.63 on Tuesday, then took off, climbing to a daily high of $10.78 in the afternoon. The move was in direct contrast to the general market trend with both the Dow Jones Industrial Average and S&P 500 index down for the day.
- Business Wire
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
CAMBRIDGE, Mass., November 30, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that the first patient has been enrolled in the SER-155 Phase 1b study. SER-155 is an investigational, oral, cultivated microbiome therapeutic. The consortia is a rationally-designed selection of bacteria optimized to enhance desired pharmacological properties to reduce the incidence of gastrointestinal bacterial infections, bacteremia and graft-versus-host dis
- Business Wire
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., November 24, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 – December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website.
